Private Asset Management Inc Gilead Sciences, Inc. Transaction History

Private Asset Management Inc

$419 Million
Q3 2023

A detailed history of Private Asset Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Private Asset Management Inc holds 53,939 shares of GILD stock, worth $4.98 Million. This represents 0.96% of its overall portfolio holdings.

Number of Shares

53,939

Previous 58,164 7.26%

Holding current value

$4.98 Million

Previous $4.48 Million 9.82%

% of portfolio

0.96%

Previous 0.87%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 20, 2023	SELL	$73.94 - $80.67 $312,396 - $340,830	-4,225 Reduced 7.26%	53,939 $4.04 Million
Q2 2023 Jul 05, 2023	SELL	$76.01 - $86.7 $745,734 - $850,613	-9,811 Reduced 14.43%	58,164 $4.48 Million
Q1 2023 Apr 04, 2023	SELL	$77.31 - $88.08 $235,022 - $267,763	-3,040 Reduced 4.28%	67,975 $5.64 Million
Q4 2022 Jan 04, 2023	SELL	$62.32 - $89.47 $384,452 - $551,940	-6,169 Reduced 7.99%	71,015 $6.1 Million
Q3 2022 Oct 04, 2022	BUY	$59.54 - $68.01 $13,813 - $15,778	232 Added 0.3%	77,184 $4.76 Million
Q2 2022 Jul 06, 2022	SELL	$57.72 - $65.01 $464,241 - $522,875	-8,043 Reduced 9.46%	76,952 $4.76 Million
Q1 2022 Apr 04, 2022	SELL	$57.92 - $72.58 $1.58 Million - $1.98 Million	-27,275 Reduced 24.29%	84,995 $5.05 Million
Q4 2021 Jan 03, 2022	SELL	$64.88 - $73.64 $141,762 - $160,903	-2,185 Reduced 1.91%	112,270 $8.15 Million
Q3 2021 Oct 04, 2021	SELL	$67.69 - $73.03 $477,282 - $514,934	-7,051 Reduced 5.8%	114,455 $8 Million
Q2 2021 Jul 06, 2021	BUY	$63.47 - $69.35 $144,457 - $157,840	2,276 Added 1.91%	121,506 $8.37 Million
Q1 2021 Apr 02, 2021	BUY	$60.0 - $68.46 $848,940 - $968,640	14,149 Added 13.46%	119,230 $7.71 Million
Q4 2020 Jan 05, 2021	BUY	$56.65 - $64.55 $537,438 - $612,385	9,487 Added 9.92%	105,081 $6.12 Million
Q3 2020 Oct 06, 2020	BUY	$62.1 - $78.08 $310,810 - $390,790	5,005 Added 5.52%	95,594 $6.04 Million
Q2 2020 Jul 06, 2020	SELL	$72.34 - $84.0 $822,433 - $954,996	-11,369 Reduced 11.15%	90,589 $6.97 Million
Q1 2020 Apr 02, 2020	SELL	$62.63 - $80.22 $737,468 - $944,590	-11,775 Reduced 10.35%	101,958 $7.62 Million
Q4 2019 Jan 03, 2020	BUY	$61.62 - $67.78 $279,508 - $307,450	4,536 Added 4.15%	113,733 $7.39 Million
Q3 2019 Oct 02, 2019	BUY	$62.51 - $69.0 $423,192 - $467,130	6,770 Added 6.61%	109,197 $6.92 Million
Q3 2019 Oct 02, 2019	SELL	$62.51 - $69.0 $293,797 - $324,300	-4,700 Reduced 4.39%	102,427 $6.92 Million
Q2 2019 Jul 02, 2019	SELL	$61.87 - $69.38 $156,531 - $175,531	-2,530 Reduced 2.31%	107,127 $7.24 Million
Q1 2019 Apr 03, 2019	SELL	$62.53 - $70.05 $161,327 - $180,729	-2,580 Reduced 2.3%	109,657 $7.13 Million
Q4 2018 Jan 08, 2019	SELL	$60.54 - $79.0 $754,510 - $984,577	-12,463 Reduced 9.99%	112,237 $7.02 Million
Q3 2018 Oct 02, 2018	BUY	$71.28 - $78.92 $187,822 - $207,954	2,635 Added 2.16%	124,700 $9.63 Million
Q2 2018 Jul 23, 2018	SELL	$64.88 - $75.68 $78,829 - $91,951	-1,215 Reduced 0.99%	122,065 $8.65 Million
Q2 2018 Jul 10, 2018	BUY	$64.88 - $75.68 $48,984 - $57,138	755 Added 0.62%	123,280 $9.29 Million
Q1 2018 Apr 06, 2018	SELL	$72.84 - $88.8 $637,641 - $777,355	-8,754 Reduced 6.67%	122,525 $9.24 Million
Q4 2017 Jan 05, 2018	SELL	$71.15 - $83.52 $791,614 - $929,243	-11,126 Reduced 7.81%	131,279 $9.41 Million
Q3 2017 Oct 04, 2017	BUY	$72.11 - $85.47 $9.44 Million - $11.2 Million	130,867 Added 1134.23%	142,405 $11.5 Million
Q3 2017 Oct 03, 2017	BUY	$72.11 - $85.47 $832,005 - $986,152	11,538	11,538 $11.5 Billion

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Private Asset Management Inc with notifications on news.

Account

Private Asset Management Inc Gilead Sciences, Inc. Transaction History